Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386139 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 881
- Enrollment target
NCT00386139: Completed Phase 3 study, sponsored by Novartis.
NCT00386139 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 881 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00386139, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 881 participants
- Enrollment target
Study Summary
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
Interventions
- DRUG Aliskiren/HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 881 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00386139 record still lists
NCT00386139 is an interventional study that assigns participants to a tested intervention. The registered 881 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 1 intervention - of which Aliskiren/HCTZ is the first listed.
NCT00386139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00386139 about?
NCT00386139 is a clinical study titled "A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients". Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
What is the current status of trial NCT00386139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 881 participants. The study started on 2006-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00386139?
The interventions under investigation include: Aliskiren/HCTZ (DRUG).
Who is sponsoring clinical trial NCT00386139?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00386139's enrollment target sits among peer trials
881 367th of 2000 higher than 1,634 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia